Adherium (ADR.ASX) has announced it has surpassed its calendar year 2025 device shipment targets, delivering 4,666 devices against a goal of 4,000, including 2,034 RPM devices against a target of 2,000.
RPM Shipments Exceed Targets
Adherium shipped 2,034 Remote Patient Monitoring (RPM) devices, exceeding its CY2025 target of 2,000.
Total device shipments reached 4,666, surpassing the company's CY2025 goal of 4,000.
This performance reinforces the company's strategy of using RPM as a key growth driver.
Growth Trajectory Continues
The company remains on track to achieve its ambitious goal of 10,000 active RPM patients by the end of CY2026.
Recent quarter-to-date RPM subscription revenue shows an increase, with RPM device shipments rising to 756 in October to November 2025, representing an 83.1% quarter-on-quarter uplift compared to 413 in the previous quarter.
The company's management guidance remains unchanged, indicating confidence in continued expansion.
Strategic Context and Partnerships
The annual report highlights strong US RPM momentum and expanded Hailie Smartinhaler interoperability, including compatibility with AIRSUPRA and Breztri.
Partnerships with organisations such as Allergy Partners and others are instrumental in scaling RPM deployments across the United States.
Focus on clinical evidence from studies like the Intermountain Health iCARE programme aims to strengthen payer and provider adoption, showcasing the platform's value in improving patient outcomes and potentially reducing healthcare costs.
Key Investor Considerations
The company's strategy relies heavily on the successful execution of its RPM scaling plans, which presents an inherent commercial scale-up risk.
Funding and liquidity remain critical considerations, with Adherium continuing to rely on capital raising activities to support its operations and growth initiatives.
The evolving regulatory and reimbursement environment for remote patient monitoring in key markets, particularly the US, is a key factor influencing long-term revenue growth and operational stability.
Outlook on RPM Growth
Adherium's proactive achievement of its device shipment targets ahead of schedule validates its focused RPM strategy. While operational execution and continued funding remain key areas for investor scrutiny, the company's trajectory towards its 10,000 active RPM patient goal by end CY2026 positions it for significant growth in the remote patient monitoring market.
